TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
BHP Shares Fall as Jansen Potash Project Costs Surge 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
LIBOURNE, France and DURHAM, N.C., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Ceva Santé Animale and Zoion Pharma Inc. announced today that they have entered into a collaboration to develop an epithelial sodium channel (ENaC) inhibitor to treat veterinary ocular surface diseases characterized by a lack of surface hydration, such as keratoconjunctivitis sicca (KCS) commonly called dry eye. Under the agreement, Ceva gains worldwide development and commercial rights to ZP-1 (P-1046). ZP-1 has successfully completed a proof-of-concept clinical trial in canine KCS. ZP-1 (P-1046) was originally discovered by Parion Sciences, Inc. and licensed to Zoion Pharma for veterinary use.
|
|||||||||
“KCS is a disease that causes much pain and discomfort, particularly in dogs. If left untreated, severe cases may lead to blindness,” said Jon Alšėnas DVM, President and CEO of Zoion Pharma. “Ceva is the ideal partner to bring this potentially very exciting new therapy to companion animals and their owners around the world.”
Financial terms of the collaboration were not disclosed.
About Ceva Santé Animale:
Ceva Santé Animale was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Its headquarters are in Libourne, France.
About Zoion Pharma:
Zoion Pharma is dedicated to the goal of identifying, sourcing and developing novel or overlooked drugs specifically for use in the treatment of companion animal diseases of high unmet medical need.
About Parion Sciences:
Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the lung or eye. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and leverages its scientific expertise in epithelial biology to expand the company’s platforms and novel chemical compounds into new potential indications to treat mucosal defects.
CONTACT: Jon Alsenas [email protected]
